ATE207346T1 - Orale pharmazeutische zusammensetzungen mit sexualhormonen - Google Patents

Orale pharmazeutische zusammensetzungen mit sexualhormonen

Info

Publication number: ATE207346T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; compositions containing; oral pharmaceutical; surfactant; propylene glycol
Prior art date: 1996-04-26

Application number

AT97920854T

Other languages

English (en)

Inventor

Elizabeth Anne Perry

Susan Gerrard Chandler

Josephine Joan Chri Ferdinando

Park Monkton

Original Assignee

Scherer Technologies Inc R P

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-26

Filing date

1997-04-28

Publication date

2001-11-15

1997-04-28 Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P

2001-11-15 Application granted granted Critical

2001-11-15 Publication of ATE207346T1 publication Critical patent/ATE207346T1/de

Links

229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
239000008203 oral pharmaceutical composition Substances 0.000 title 1
230000001568 sexual effect Effects 0.000 title 1
239000004094 surface-active agent Substances 0.000 abstract 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
150000004665 fatty acids Chemical class 0.000 abstract 2
230000002209 hydrophobic effect Effects 0.000 abstract 2
239000003921 oil Substances 0.000 abstract 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 abstract 1
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
239000004359 castor oil Substances 0.000 abstract 1
235000019438 castor oil Nutrition 0.000 abstract 1
229930182833 estradiol Natural products 0.000 abstract 1
125000005456 glyceride group Chemical group 0.000 abstract 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
239000003163 gonadal steroid hormone Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
-1 polyoxyethylene Polymers 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
229940026235 propylene glycol monolaurate Drugs 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
150000003626 triacylglycerols Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT97920854T 1996-04-26 1997-04-28 Orale pharmazeutische zusammensetzungen mit sexualhormonen ATE207346T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9608719.2A GB9608719D0 (en)	1996-04-26	1996-04-26	Pharmaceutical compositions
PCT/GB1997/001247 WO1997040823A1 (en)	1996-04-26	1997-04-28	Oral pharmaceutical compositions containing sex hormones

Publications (1)

Publication Number	Publication Date
ATE207346T1 true ATE207346T1 (de)	2001-11-15

Family

ID=10792737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97920854T ATE207346T1 (de)	1996-04-26	1997-04-28	Orale pharmazeutische zusammensetzungen mit sexualhormonen

Country Status (12)

Country	Link
EP (1)	EP0904064B1 (de)
JP (1)	JP5088804B2 (de)
KR (1)	KR100511133B1 (de)
AT (1)	ATE207346T1 (de)
AU (1)	AU2707497A (de)
DE (1)	DE69707669T2 (de)
DK (1)	DK0904064T3 (de)
ES (1)	ES2164339T3 (de)
GB (1)	GB9608719D0 (de)
PT (1)	PT904064E (de)
WO (1)	WO1997040823A1 (de)
ZA (1)	ZA973653B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
DE60040214D1 (de)	1999-02-26	2008-10-23	Shionogi & Co	Kaubare weichkapseln mit verbesserten verabreichungseigenschaften sowie verfahren zu deren herstellung
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en)	1999-04-01	2003-11-25	R.P. Scherer Technologies, Inc.	Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
PL195163B1 (pl) *	1999-04-01	2007-08-31	Organon Nv	Kompozycja farmaceutyczna zawierająca undekanian testosteronu, zastosowanie undekanianu testosteronu i zastosowanie zawierającej go kompozycji farmaceutycznej
GB9907715D0 (en) *	1999-04-01	1999-05-26	Scherer Corp R P	Pharmaceutical compositions
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
AU2001284772A1 (en) *	2000-08-10	2002-02-25	Delsys Pharmaceutical Corporation	Improved solid pharmaceutical dosage formulation of hydrophobic drugs
FR2818905A1 (fr) *	2000-12-28	2002-07-05	Cll Pharma	Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
DK1392254T3 (da)	2001-04-20	2007-07-02	Univ British Columbia	Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
HUP0400263A2 (hu)	2001-06-21	2005-03-29	Pfizer Products Inc.	Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
WO2003002095A1 (fr) *	2001-06-28	2003-01-09	Chugai Seiyaku Kabushiki Kaisha	Preparation d'une micro-emulsion de type huile-eau
FR2832065B1 (fr)	2001-11-13	2004-11-05	Besins Int Belgique	Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
JO2505B1 (en) *	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN1299686C (zh) *	2003-04-03	2007-02-14	上海医药工业研究院	黄体酮半固体骨架制剂的组合物
EP1617734A1 (de) *	2003-04-17	2006-01-25	Boehringer Ingelheim International GmbH	Multivitamin- und mineralstoffergänzung für schwangere
JP2005047851A (ja) *	2003-07-29	2005-02-24	Nisshin Pharma Inc	ユビデカレノン含有組成物
DE60303854T2 (de)	2003-11-11	2006-08-10	Mattern, Udo	Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
US8492369B2 (en)	2010-04-12	2013-07-23	Clarus Therapeutics Inc	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
EP1871384A4 (de) *	2005-04-15	2012-01-25	Clarus Therapeutics Inc	Systeme zur pharmazeutischen verabreichung hydrophober wirkstoffe und zusammensetzungen damit
PT2068825E (pt)	2006-10-04	2011-02-11	M & P Patent Ag	Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
EP1961412A1 (de) *	2006-12-27	2008-08-27	LEK Pharmaceuticals D.D.	Selbstmikroemulgierende Arzneimittelabgabesysteme
GB0807605D0 (en)	2008-04-28	2008-06-04	Diurnal Ltd	Lipid composition
AU2014200332B2 (en) *	2008-04-28	2016-10-06	Diurnal Limited	Lipid composition
US8309107B2 (en)	2008-10-06	2012-11-13	Banner Pharmacaps, Inc.	Stable solutions of orlistat for pharmaceutical dosage forms
US8686006B2 (en)	2008-10-22	2014-04-01	Santen Pharmaceutical Co., Ltd.	Pharmaceutical composition for improving intestinal absorption
US11304960B2 (en) *	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US9011908B2 (en)	2009-04-06	2015-04-21	Banner Life Sciences Llc	Progesterone solutions for increased bioavailability
WO2011055269A1 (en) *	2009-11-09	2011-05-12	Pfizer Inc.	Delivery carrier
EP2519230B1 (de)	2009-12-31	2018-10-10	Marius Pharmaceuticals LLC	Modulation der löslichkeit, der stabilität, der absorption, des stoffwechsels und des pharmakokinetischen profils lipophiler wirkstoffe mithilfe von sterolen
ES2525520T3 (es) *	2010-04-12	2014-12-26	Clarus Therapeutics, Inc.	Formulaciones orales de éster de testosterona y métodos para tratar la deficiencia de testosterona con las mismas
CN103705462B (zh) *	2010-04-12	2016-08-31	克劳拉斯医疗有限公司	口服睾酮酯制剂以及包含其的治疗睾酮缺乏症的方法
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US8900631B2 (en)	2011-04-28	2014-12-02	Health Science Funding, LLC	Dosage form to increase prasterone bioavailability
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
FR2988609B1 (fr) *	2012-03-30	2015-09-04	Commissariat Energie Atomique	Formulation pour l'hormonotherapie
RU2740059C2 (ru) *	2012-06-18	2020-12-31	Терапьютиксмд, Инк.	Капсулы с растворимым эстрадиолом для интравагинального введения
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
FR2997627B1 (fr)	2012-11-08	2015-01-16	Hra Pharma Lab	Produit de co-micronisation comprenant de l'ulipristal acetate
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
CN105188670B (zh) *	2013-03-15	2018-11-02	马留斯医药有限责任公司	乳液制剂
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
MX2016014281A (es)	2014-05-22	2017-02-22	Therapeuticsmd Inc	Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US9925200B2 (en)	2014-06-17	2018-03-27	Merck Sharp & Dohme B.V.	Stable formulations of testosterone undecanoate
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017105512A1 (en)	2015-12-18	2017-06-22	Proinvet Innovations S.A.	Formulations and methods for controlling the reproductive cycle and ovulation
US20170281646A1 (en) *	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
WO2017173191A1 (en) *	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
AU2017239645A1 (en)	2016-04-01	2018-10-18	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
BR112020010519A2 (pt)	2017-11-27	2020-10-20	Umecrine Cognition Ab	formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
EP3824296A4 (de)	2018-07-20	2022-04-27	Lipocine Inc.	Lebererkrankung
US20220192996A1 (en) *	2019-03-29	2022-06-23	Sekisui Chemical Co., Ltd.	Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product
US12403146B2 (en)	2019-10-30	2025-09-02	Marius Pharmaceuticals, Inc.	Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
JP7822939B2 (ja) *	2020-02-05	2026-03-03	ニューロクラインユーケーリミテッド	テストステロン含有医薬組成物
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
US20250319101A1 (en)	2021-10-08	2025-10-16	Chemo Research, S.L.	Oral pharmaceutical compositions of progesterone and estradiol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9405304D0 (en) *	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs

1996
- 1996-04-26 GB GBGB9608719.2A patent/GB9608719D0/en active Pending
1997
- 1997-04-25 ZA ZA9703653A patent/ZA973653B/xx unknown
- 1997-04-28 JP JP53867897A patent/JP5088804B2/ja not_active Expired - Lifetime
- 1997-04-28 WO PCT/GB1997/001247 patent/WO1997040823A1/en not_active Ceased
- 1997-04-28 DE DE69707669T patent/DE69707669T2/de not_active Expired - Lifetime
- 1997-04-28 PT PT97920854T patent/PT904064E/pt unknown
- 1997-04-28 KR KR1019980708569A patent/KR100511133B1/ko not_active Expired - Lifetime
- 1997-04-28 AU AU27074/97A patent/AU2707497A/en not_active Abandoned
- 1997-04-28 AT AT97920854T patent/ATE207346T1/de active
- 1997-04-28 EP EP97920854A patent/EP0904064B1/de not_active Expired - Lifetime
- 1997-04-28 ES ES97920854T patent/ES2164339T3/es not_active Expired - Lifetime
- 1997-04-28 DK DK97920854T patent/DK0904064T3/da active

Also Published As

Publication number	Publication date
JP2000510458A (ja)	2000-08-15
GB9608719D0 (en)	1996-07-03
JP5088804B2 (ja)	2012-12-05
AU2707497A (en)	1997-11-19
KR100511133B1 (ko)	2006-04-28
EP0904064B1 (de)	2001-10-24
DE69707669T2 (de)	2002-07-11
DE69707669D1 (de)	2001-11-29
PT904064E (pt)	2002-02-28
ZA973653B (en)	1997-11-19
EP0904064A1 (de)	1999-03-31
KR20000065025A (ko)	2000-11-06
WO1997040823A1 (en)	1997-11-06
DK0904064T3 (da)	2001-12-17
ES2164339T3 (es)	2002-02-16

Legal Events

Date	Code	Title	Description
2002-04-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE207346T1 (de)	2001-11-15	Orale pharmazeutische zusammensetzungen mit sexualhormonen
US5532002A (en)	1996-07-02	Gelatin pharmaceutical formulations
US5738871A (en)	1998-04-14	Pharmaceutical formulations
NO20014719L (no)	2001-10-24	Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
KR100666016B1 (ko)	2007-01-10	테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제
KR940018091A (ko)	1994-08-16	불포화 지방산을 포함하는 처방
ES2195175T3 (es)	2003-12-01	Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
ES2174814T3 (es)	2002-11-16	Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
ES2101574T3 (es)	1997-07-01	Composicion administrable por via oral apta para formar una microemulsion.
KR970704433A (ko)	1997-09-06	의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition)
AR029615A1 (es)	2003-07-10	Una formulacion farmaceutica para la administracion oral
UY26303A1 (es)	2001-03-16	Composiciones farmacéuticas para administración oral y tópica
GR3035613T3 (en)	2001-06-29	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
DK0938339T3 (da)	2002-10-14	Formuleringer til topisk anvendelse indeholdende vitamin-E acetat
IL122434A (en)	2003-07-06	Compositions of mixed colloidal particles in an aqueous environment for sustained delivery of bioactive agents and pharmaceutical preparations therewith
JPH11199493A (ja)	1999-07-27	皮膚外用剤組成物
MY130474A (en)	2007-06-29	Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
NZ506579A (en)	2002-11-26	Palatable oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
JP2000159660A (ja)	2000-06-13	シクロスポリンカプセル剤